| Trial ID: | L0135 |
| Source ID: | NCT04857437
|
| Associated Drug: |
PF-07202954
|
| Title: |
Study in Healthy Adults Evaluating PF-07202954
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-Alcoholic Fatty Liver Disease|Liver Fibrosis
|
| Interventions: |
Drug: PF-07202954 Repeat Dose|Drug: PF-07202954 Single Dose|Drug: Placebo
|
| Outcome Measures: |
Number of Subjects reporting treatment emergent adverse events (AEs)|Incidence of treatment emergent clinical laboratory abnormalities|Incidence of treatment emergent vital signs|Incidence of treatment emergent Electrocardiogram (ECG) abnormalities|Maximum plasma concentration (C[max])|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area under the plasma concentration time AUC[last])|Area Under the Curve from Time Zero to Extrapolated Infinite Time (AUCinf)|Cmax|Tmax|AUClast|AUCinf|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)|Time measured for plasma concentration to decrease by one half (Terminal half-life) [t(1/2)].|Amount of unchanged drug recovered in urine during dosing interval (AE[tau])|Percent of dose recovered in urine as unchanged drug over dosing interval (AE[tau%])|Renal Clearance (CLr)|AEs|ECG abnormalities
|
| Sponsor/Collaborators: |
Pfizer
|
| Gender: |
All
|
| Age: |
18 Years to 65 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
12
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
|
| Start Date: |
May 13, 2021
|
| Completion Date: |
September 17, 2021
|
| Results First Posted: |
--
|
| Last Update Posted: |
November 15, 2021
|
| Locations: |
New Haven Clinical Research Unit, New Haven, Connecticut, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT04857437
|
